ImmunityBio reported Q2 2026 net product revenue of $50.7 million, a 92% year-over-year increase and the eighth consecutive quarter of sequential growth driven by ANKTIVA adoption. First-half revenue reached $94.8 million, up 121%. The company holds $357.4 million in cash and marketable securities as of June 30, 2026. Regulatory updates include a UAE marketing authorization for ANKTIVA across multiple indications and FDA acceptance of an sBLA with a PDUFA date of January 6, 2027. ImmunityBio also secured exclusive U.S. rights to Tokyo-172 BCG via an agreement with Japan BCG Laboratory. The company operates in the biotechnology industry, developing and commercializing immunotherapies for cancer.

On July 29, 2026, the Emirates Drug Establishment granted marketing authorization for ANKTIVA in the United Arab Emirates across two indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's global regulatory footprint to 34 countries, making the UAE the fifth jurisdiction to authorize the therapy. The filing details clinical evidence from trials QUILT-3.032 and QUILT-3.055 supporting these indications. ImmunityBio operates in the biotechnology industry, focusing on developing immunotherapies for cancer.